Dementia of the Alzheimer's Type
Conditions
Keywords
Alzheimer, Mesenchymal Stem Cells, Umbilical Cord Blood
Brief summary
The primary purpose of this study is to evaluate the safety and the tolerability of NEUROSTEM®-AD (Human Umbilical Cord Blood Derived Mesenchymal Stem Cells) and to assess the maximum tolerated dose (MTD). This study is also to investigate the efficacy of this study drug in patients with dementia of Alzheimer's type.
Detailed description
Most of the treatments for Alzheimer disease are chemical drug that is designed to temporarily increase acetylcholine, based on the cholinergic hypothesis. These drugs can improve the symptoms but is not able to inhibit the disease progression. New drugs from the disease have been developed but they have not been successful yet. Mesenchymal stem cells (MSC) are capable of differentiating into various tissues. Due to the characteristics of the cells it has been widely investigated in tissue regeneration. In addition, the paracrine effect of MSC in microenvironment has been recently reported. MSC has been developed as an immunomodulation cell therapy product because it has been known that it does not cause immunological rejection in allo- and xeno-transplantation. Clinical studies showed that umbilical cord blood-derived MSC is immunologically stable and not toxic. This study is to evaluate the safety and the tolerability of NEUROSTEM®-AD (Human Umbilical Cord Blood Derived Mesenchymal Stem Cells) and to assess the maximum tolerated dose (MTD). This study is also to investigate the efficacy of this study drug in patients with dementia of Alzheimer's type.
Interventions
DOSE A - 250,000 cells per 5 uL per 1 entry site, 3 million cells per brain DOSE B - 500,000 cells per 5 uL per 1 entry site, 6 million cells per brain
Sponsors
Medipost Co Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Korean men and women who are age 50 or older * Dementia as determined by DSM-IV criteria * Probable alzheimer's disease as determined by NINCDS-ADRDA criteria * K-MMSE score in the range of 10 to 24 * Positive result of PIB-PET imaging (SUV \> 1.5,when comparing the result for the cerebellum with the result for the frontal lobe) * Voluntarily participating subject who sign the consent form
Exclusion criteria
* Subject with psychological diseases (i.e. depression, schizophrenia, bipolar disorder, etc) * Subject with dementia caused by other than Alzheimer's disease (i.e. infection of central nervous system, Creutzfeld-Jacob disease, severe head trauma, Pick's disease, Huntington's disease, and Parkinson's disease) * Subject with vascular dementia as determined by the clinical criteria of DSM IV and the imaging criteria of Erkinjuntii * Subject with severe white matter hyperintensities (WMH); Severe WMH is defined that length of the deep white matter is 25 mm or longer and length of the periventricular capping/banding is 10 mm or longer. * Subject who have had stroke in 3 months. * Subject with liver disease (two times higher than normal range of ALT/AST) * Subject with severe kidney failure (1.5mg/dL of serum creatinine or more) * Pregnant women or lactating women * Hemoglobin \< 9.5g/dL for men, \< 9.0 g/dL for women; Total WBC count \< 3000/mm3; Total bilirubin ≥ 3 mg/dL * Subject who is suspect to have active lung diseases, based on check X-ray result from Visit 1 * Women of childbearing age who reject to practice contraception * Subject who have been excluded in the subject selection process for this study before * A platelet count \< 150,000/mm3; PT ≥ 1.5; INR or aPTT ≥ 1.5 X control * Subject with cancer * History of alcohol or drug abuse * Subject who cannot undergo MRI, CT, or PET screening * Subject who cannot undergo anesthesia or stereotactic brain injection * Subject who is determined inappropriate by the investigators
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with Adverse event | 12 weeks from post-administration | Number of participants with adverse event, number of participants with normal range of vital signs, mixed lymphocyte reaction, and laboratory examination |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes from the baseline in ADAS-cog at 12 weeks post-dose | 12 weeks from post-administration | Changes from the baseline in ADAS-cog, S-IADL, K-MMSE, CGA-NPI, ADAS-Cog, serum transthyretin, amyloid beta and tau in cerebrospinal fluid, PIB-PET and FDG-PET at 12 weeks post-dose. |
Countries
South Korea
Outcome results
None listed